https://www.selleckchem.com/products/cb-5083.html
Almost all patients received chemotherapy. 75.3% received radiotherapy, 23.5% received hormonal therapy and 6.2% received Trastuzumab. With a median follow-up of 54 months, 18.5% developed loco-regional recurrence and 34.6% relapsed distally. Five-year OS was 66.0%. On multivariate analysis adjuvant radiotherapy correlated with better OS ( .0001), and tumor size 5 cm, nodal involvement and LVI correlated with worse OS, ( = .019, = .021, = .028, respectively). There were no survival differences with respect to age, triple negati
Like
Comment
Share
